Maxwell's preclinical pneumonia drug gets FDA QIDP designation

The FDA granted the designation in May; Maxwell says human trials are planned for 2027.

By · Published · Updated

Primary source: x.com

Why it matters

The designation gives Maxwell a regulatory development path.

A blue-gloved hand holds a vial beside a microscope and test tubes, while a monitor displays a human torso and colorful microbes.

Maxwell Biosciences's experimental pneumonia drug received FDA Qualified Infectious Disease Product status in May. Founder Scotch McClure (@scotchmcclure) wrote about the designation in an October 25th post on X. The candidate remains preclinical and has not been tested in people.…

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Reader comments

Conversation for this story loads after sign-in.